Introduction
The human BK polyomavirus (BKPyV) and JC polyomavirus (JCPyV) are ubiquitous pathogens [1] . Infection by these human polyomaviruses usually takes place in childhood and is asymptomatic, followed by latency in the kidney and the urinary tract [2] . In immunocompromised individuals, BKPyV and JCPyV can reactivate and cause severe disease. In the case of organ transplant recipients on an immunosuppressive regimen, BKPyV reactivation and replication in the renal tubular epithelium lead to polyomavirusassociated nephropathy (PVAN) in about 10% of renal transplant patients and hemorrhagic cystitis in bone marrow transplant patients. Approximately 50% of patients with PVAN ultimately progress to renal failure, leaving them in need of another kidney transplant [2] . In about 3%-5% of 2 Evidence-Based Complementary and Alternative Medicine HIV/AIDS patients and in multiple sclerosis patients undergoing immunomodulatory therapy, the immunosuppressed state triggers reactivation of latent JCPyV, whose lytic infection of oligodendrocytes results in the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML). Death usually occurs 1-2 years after PML diagnosis [3] .
Recent advances in diagnostic technology have permitted rapid quantification of BKPyV copy numbers in patients, allowing the dosage of immunosuppressants to be lowered when high levels of BKPyV replication are detected. However, reduction of immunosuppression as a strategy to limit BKPyV replication in renal transplant patients was not correlated with significantly decreased rates of renal graft loss due to PVAN and carries a risk of graft rejection [2] . Treatment of PML caused by JCPyV reactivation remains focused on reconstituting the patient's immune system. Combined antiretroviral therapy is the usual treatment for AIDS patients with detectable JCPyV in the cerebrospinal fluid and can reduce the rate of JCPyV reactivation, but the two-year mortality rate of PML patients remained high at 50%-60% [4] . In a subset of PML patients, their immune system becomes overly activated by immune reconstitution and produces an inflammatory response to tissues affected by JCPyV reactivation, leading to PML-immune reconstitution inflammatory syndrome (PML-IRIS); such cases could necessitate measures to lower the patients' immune activity [5, 6] . Also, PML that develops in patients with hematological malignancy can be difficult to treat because chemotherapy interferes with the production of immune cells needed for the immune reconstitution strategy against JCPyV [7] . For these reasons, bolstering patients' immune function is of limited usefulness in combating reactivated BKPyV and JCPyV. A number of drugs that are not specific anti-BKPyV or anti-JCPyV agents are currently in clinical use for BKPyV or JCPyV infection. Among them, cidofovir, leflunomide, fluoroquinolones, and intravenous immunoglobulins are commonly used to treat PVAN due to BKPyV reactivation; however, these drugs have degrees of hepatic, renal, or cardiac toxicity [8] [9] [10] . Cidofovir and leflunomide have been used to treat JCPyV reactivation, but reports are scant and clinical outcomes varied [7] . Therefore, the development of effective anti-BKPyV and antiJCPyV drugs is sorely needed.
The binding of a virus to its host cell's receptor determines tropism and tissue-specific pathology; thus, blocking this binding is a promising approach for drug development. The cell surface receptors for BKPyV are disialic acid gangliosides GD1b, GT1b, GD3, and GD2 [11] . JCPyV recognizes the complex consisting of a serotonin receptor and the sialic acidcontaining pentasaccharide LSTc [12, 13] . With the increasing use of medicinal herbs in the development of antiviral drugs, the extracts of many Chinese medicinal herbs have been found to inhibit the progression of the viral life cycle at the stages of entry, replication, assembly, and release, as well as targeting specific virus-host interactions [14] . In this study, we screened the extracts of approximately 40 Chinese medicinal herbs, among which we found Rhodiolae Kirliowii Radix et Rhizoma and Crataegus Pinnatifidae Fructus extracts to effectively inhibit the hemagglutination activity of BKPyV and JCPyV virus-like particles (VLPs). The two herbal extracts were further examined for their ability to inhibit BKPyV and JCPyV infection of human kidney and neuroglial cells, respectively, and the presumed mechanism by which Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus inhibit BKPyV and JCPyV infection was also verified.
Materials and Methods

Purification of VLPs from Yeast Expressing BKPyV and
JCPyV VP1s. Expression of VLPs from yeast and their purification has been previously described in detail [15] . The plasmids pFXBKV1 and pFXJCV1, bearing the VP1 genes of BKPyV and JCPyV, respectively, were transfected into Saccharomyces cerevisiae (INVSC1 yeast cells). Galactose was added to the cultures to a final concentration of 3% to induce the expression of the VP1 proteins. The yeast cells were harvest and lysed, and the supernatants of the VP1-containing lysates were subjected to centrifugation through a 20% sucrose cushion and then through a 10%-30% sucrose gradient. Fractions with hemagglutination activity were collected and concentrated with Centricon filters (Millipore, Billerica, MA).
Preparation of Herbal Extracts.
Herbal power was purchased from Chuang Song Zong Pharmaceutical Co., Ltd. (Kaohsiung, Taiwan), and KO DA Pharmaceutical Co., Ltd. (Taoyuan, Taiwan). Herbal power was diluted in phosphatebuffered saline (PBS) to a final concentration of 100 mg/mL. After centrifugation at 14,000 rpm for 30 min, the supernatant was filtered through 0.45 m and 0.22 m filter paper and stored at −20 ∘ C until use.
Hemagglutination Inhibition Assay.
Before being analyzed for hemagglutination inhibition activity on BKPyV and JCPyV VLPs, herbal extracts were first tested to ensure their lack of hemagglutination activity. Fifty microliters of herbal extract (100 mg/mL) was diluted in twofold steps with PBS in a U-shaped microtiter plate, to which 50 L of 0.7% (v/v) human type O erythrocyte suspension was then added. After 1 h of incubation, herbal extracts that did not exhibit observable hemagglutination activity were assayed for the ability to inhibit hemagglutination by BKPyV or JCPyV VLPs. The hemagglutination inhibition assay was performed as the previous report with a minor modification [16] . Briefly, 25 L of herbal extract was diluted in twofold steps with PBS in a U-shaped microtiter plate, to which 2 hemagglutination units (HAU) of BKPyV VLPs or 8 HAU of JCPyV VLPs in 25 L were added per well, followed by 50 L of 0.7% (v/v) human type O erythrocyte suspension. After 1 h of incubation, the hemagglutination inhibition activity of each herbal extract was defined as the highest dilution that resulted in complete inhibition of VLPs' hemagglutination activity. fetal bovine serum (Invitrogen), 5 g/mL transferrin (Millipore), 5 g/mL insulin (Sigma-Aldrich, St. Louis, MO, USA), 400 ng/mL hydrocortisone (Sigma-Aldrich), and 5 ng/mL sodium selenite (Sigma-Aldrich). SVG-A cells, a gift from Dr. W. Atwood (Brown University, RI, USA), were maintained in minimal essential medium supplemented with 10% fetal bovine serum, 1% penicillin, and 1% streptomycin. The methods of propagating and purifying BKPyV and JCPyV were similar to those described previously [17] . Briefly, 320 HAU of either the UT strain of BKPyV or the Mad-4 strain of JCPyV (purified from JCI cells) [18] were propagated in HK-2 or SVG-A cells, respectively, with a change of culture medium every other week. When the cytopathic effect was evident, virus-infected cells were harvested and suspended in buffer A (10 mM Tris-HCl, 50 mM NaCl, and 0.1 mM CaCl 2 ) and lysed through three cycles of freezing and thawing at −80 ∘ C and 37 ∘ C. Viral particles in the lysate were released from cellular membranes by treatment with type V neuraminidase (Sigma-Aldrich) and then subjected to 20% sucrose cushion centrifugation and five-step CsCl gradient centrifugation. Fractions corresponding to DNA-containing virions were collected and concentrated with a Centricon filter (Millipore). [19] . Values were normalized to a vehicle-treated control, and three independent experiments were performed and used to calculate standard deviations.
Cells and Virus Propagation and
Cell Viability
Virus Labeling.
BKPyV and JCPyV were labeled with Alexa Fluor 488 according to the manufacturer's instructions (Invitrogen). Purified BKPyV or JCPyV at 1 mg/mL was dialyzed in 0.1 M carbonate-bicarbonate buffer, pH 8.0, and dye was added at a molar excess of 200 : 1. After 1 h of rocking incubation at room temperature, excess dye was removed by centrifugation using a 30,000 MWCO Centricon filter (Millipore). The mixtures were incubated on ice for 1 h and then fixed by adding 200 L of BD Cytofix, followed by washing in ice-cold PBS three times. Binding was assessed by flow cytometry. 
Flow Cytometric Scoring of Virus
Examination of Virus Binding by
Analysis of Inhibition of BKPyV and JCPyV
Immunofluorescence Assay.
Herbal extract-or vehicletreated, virus-infected cells on coverslips were fixed with cold acetone and methanol. The coverslips were blocked with normal horse serum (Invitrogen), and the cells' morphology was revealed by counterstaining with Evan's blue solution. The cells were then incubated with mouse monoclonal antibody against simian virus 40 (SV40) large T antigen (LT) (Calbiochem), which cross-reacts with BKPyV LT, or incubated with rabbit polyclonal antibody against JCPyV VP1 to detect the viral early or late protein, respectively. The primary antibody incubation was followed by incubation with Alexa Fluor 488-conjugated goat anti-mouse or anti-rabbit IgG (Molecular Probes), respectively. Stained coverslips were mounted with antifade fluorescence mounting medium. Two thousand cells per coverslip were counted under a fluorescent microscope (Olympus) for determining the percentage of positive cells.
Real-Time PCR Detection and Relative Quantification.
The cDNA was amplified using the specific primer pairs of BKV-VP1 and JCV-VP1 with 2x FAST SYBR Green Master Mix (Topgen Biotech., TW). Nucleotide sequences, 5 -TTGAGTGCTGGGTTCCTGATC-3 and 5 -GCCCCA-CACCCTGTTCATC-3 , were used as BKV-VP1 forward and reverse primers. JCV-VP1 forward and reverse primer sequence was 5 -AACAGTGTTGCTTGATGAATTTGG-3 and 5 -TCTCCACTGCTGGGAACCA-3 , respectively. The PCRs were performed in the StepOnePlus Real-Time PCR system (Applied Biosystems, USA), in accordance with the manufacturer's instructions. The cycling parameters were as follows: (i) 5 min at 95 ∘ C; (ii) 40 cycles at 95 ∘ C for 3 s and then 60 ∘ C for 30 s; and (iii) 95 ∘ C for 15 s, then 62 ∘ C for 60 s, and then 95 ∘ C for 15 s. Specimens were amplified in triplicate with appropriate nontemplate controls. Amplification data were normalized to the human control gene GAPDH expression. Quantification of relative expression was performed using the 2 −ΔΔCt relative quantification method.
Results
Screening Chinese Medicinal Herbal Extracts for Hemagglutination Inhibition Activity on BKPyV VLPs and JCPyV
VLPs. The same cell surface molecules that allow binding of BKPyV and JCPyV to host cells are also present on red blood cells, allowing these receptor molecules to mediate erythrocyte recognition and hemagglutination by BKPyV and JCPyV. Enzymatic cleavage of sugar molecules on the cell surface abolished the viruses' ability to hemagglutinate or bind to host cells [20] . Figure S1A in Supplementary Material available online at https://doi.org/10.1155/2017/5620867). Next, we tested these 16 herbal extracts for the ability to inhibit hemagglutination by BKPyV VLPs ( Figure S1B ) and JCPyV VLPs ( Figure  S1C ). Figure   S1B ), whereas, against JCPyV VLPs, both titers were 2
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( Table 1 and Figure S1C ). Thus, of the two herbal extracts, Crataegus pinnatifida Fructus has a greater hemagglutination inhibition effect on BKPyV VLPs. (Figure 3(d) ). Values were normalized to a vehicle-treated control, and three independent experiments were performed and used to calculate standard deviations. 
Assessing the Cytotoxicity of Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus Extracts in HK-
Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus Extracts Inhibit BKPyV and JCPyV
Discussion
No effective antivirals yet exist for PVAN due to BKPyV or for PML due to JCPyV. In this study, we showed that the extracts of protein expression in the infected cells decreased, and the decrease was progressively larger with increasing concentration of the extract. In addition, the two extracts' inhibitory effects appeared to be specific for the viruses, as neither extract exhibited marked cytotoxicity within the effective concentration range. Collectively, these results support the potential usefulness of Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus in the development antiBKPyV and anti-JCPyV drugs. Virus binding to host cells in the initial stage of the viral life cycle determines the specificity of viral infection and constitutes an important target of antiviral drug research and development. During polyomavirus infection, the VP1 molecule of the viral capsid binds to cellular receptors. Based on the crystallographic X-ray diffraction analysis of murine and simian (SV40) polyomaviruses [22, 23] , it is believed that the BC1 and BC2 loops of VP1 form a groove to which sugar moieties of the cellular receptors bind. BKPyV and JCPyV recognize different receptors. The receptor moiety for BKPyV is not yet confirmed; BKPyV is known to recognize N-linked (2,3) sialic acid moieties of a protein and ganglioside molecules GD1b and GT1b. JCPyV uses the serotonergic receptor 5HT 2A R and (2,6)-linked sialic acid to infect human glial cells. Thus, BKPyV and JCPyV have different specificities for different sugar moieties. Consistently, for both Rhodiolae Kirliowii Radix et Rhizoma and Crataegus Pinnatifida, we observed different hemagglutination inhibition activities toward BKPyV VLPs and JCPyV VLPs ( Table 1) .
The anti-BKPyV and anti-JCPyV drugs currently in clinical use lack specificity and have some hepatic, renal, or cardiac toxicity. More antivirals for treating BKPyV and JCPyV infections are in development, and the drug candidates primarily target three stages of the viral life cycle. The first group of such drugs includes chlorpromazine, citalopram, risperidone, ziprasidone, and mirtazapine, which act on the serotonin receptor that binds JCPyV [13, 24] , and gallic acid-based compounds, which inhibit the binding of BKPyV and JCPyV to the cell surface [25] . The second group includes retro-2 cycl and brefeldin A, which inhibit the retrograde transport of BKPyV and JCPyV to the endoplasmic reticulum [26] . The third group includes cidofovir, cytarabine, ganciclovir, and leflunomide, which work through inhibiting viral replication [27] . Because of the relative ease and low cost of obtaining BKPyV VLPs and JCPyV VLPs, we began by screening medicinal herbs for the ability to inhibit these VLPs' hemagglutination activity before proceeding to further analyses. Although assaying for inhibition of hemagglutination activity was rapid and uncomplicated, substances with intrinsic hemagglutination activity had to be excluded from this assay and thus could not be further tested for inhibition of viral infection. Our preliminary screen resulted in the exclusion of 24 Chinese medicinal herbs on the basis of having hemagglutination activity (Table 1) (Figure 3(d) (Figure 2 ). In our infection inhibition assays, the herbal extract being tested remained present during the binding of BKPyV or JCPyV to cells at 4 ∘ C and was removed along with the virus by washing with PBS only after the binding period. Thus, it is possible that, besides interfering with host cell binding by the viruses, the herbal extracts affected certain other cellular functions, leading to the observed differences in the IC 50 values for BKPyV and JCPyV. Alternatively, the two herbal extracts' differential inhibitory activities on virus cell binding may stem from the fact that BKPyV and JCPyV recognize different cellular receptors. The present data do not allow us to conclude whether Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus inhibit BKPyV and JCPyV infection through mechanisms other than inhibition of the viruses' binding to their cell surface receptors.
Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus are common Chinese medicinal herbs with a long history of therapeutic use. Rhodiolae Kirliowii Radix et Rhizoma is reputed to decrease depression, enhance work performance, eliminate fatigue, and prevent high altitude sickness [28] , whereas Crataegus pinnatifida Fructus has antihyperlipidemic and anti-inflammatory effects [29] . Recent research has also uncovered antiviral activities in , and these potential new drugs may be able to be used in combination with other drugs to achieve an enhanced antiviral effect against BKPyV and JCPyV at lower dosages, thereby reducing side effects.
Conclusions
The present study showed that the extracts of Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus inhibit BKPyV and JCPyV infection through interfering with virus binding to host cells. The two herbal medicines' antiviral effects on renal and glial cells may be useful for the treatment of PVAN and PML in the future.
